28 December 2005 
AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds
Phase II compound for improving cognitive deficits in Alzheimer’s Disease and Schizophrenia included in agreement.  

23 December 2005
Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments
KuDOS Pharmaceuticals Limited is a privately-owned UK biotechnology company, focused on the discovery and development of oncology therapies based on the inhibition of DNA repair. The total share capital of the company will be purchased for $210m cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2006.  

22 December 2005
AstraZeneca and AtheroGenics Announce Late Stage Licensing and Commercialisation Agreement for Novel Atherosclerosis Drug AGI-1067
AstraZeneca has entered into a licensing deal with AtheroGenics, Inc. (Nasdaq: AGIX) for the global development and commercialisation of their anti-inflammatory cardiovascular product candidate, AGI-1067. AGI-1067 is an investigational oral drug for the treatment of atherosclerosis, the underlying disease process that leads to heart attacks and strokes and is currently in Phase III development in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial.   

3 October 2005
SCIENCE MAGAZINE'S TOP EMPLOYER RANKING 2005
AstraZeneca moved up in ranking again this year from 5 to 4. 

27 July 2005 
ASTRAZENECA AND SCHERING AG ANNOUNCE COLLABORATION AND LICENSING AGREEMENT IN THE AREA OF ANTI-INFLAMMATORY AGENTS

27 July 2005
ASTRAZENECA AND ASTEX ANNOUNCE NEW ANTI-CANCER DRUG DISCOVERY ALLIANCE

11 July 2005
ASTRAZENECA AND AVANIR ANNOUNCE GLOBAL ALLIANCE TO DISCOVER AND DEVELOP NOVEL REVERSE CHOLESTEROL TRANSPORT ENHANCING COMPOUNDS
The alliance aims to discover, develop and commercialise Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.

4 July 2005
ASTRAZENECA TO START PHASE III TRIALS WITH ZACTIMA TM (ZD6474) – A NOVEL TARGETED LUNG CANCER TREATMENT
This is a unique once-daily oral therapy that selectively targets key signalling pathways in cancer including: vascular endothelial growth factor (VEGF) receptor signalling resulting in inhibition of tumour angiogenesis; and epidermal growth factor (EGF) receptor signalling which may lead to direct inhibition of cancer cell proliferation and survival. It also inhibits RET kinase which may be important in certain tumours.

24 May 2005
TOP PSYCHIATRY RESEARCHERS HONOURED WITH INTERNATIONAL CAREER DEVELOPMENT AWARD
American Psychiatric Association and AstraZeneca Reward ‘2004 Young Minds in Psychiatry’ Winners.

24 March 2005
TACKLING TB - OUR CONTINUED COMMITMENT TO THE FIGHT
AstraZeneca is committed to helping in the fight against TB - in two different ways.

17 January 2005 
ASTRAZENECA STARTS CONSTRUCTION OF $10 M PROCESS R&D FACILITY IN BANGALORE
This new unit, one of the four other AZ PR&D facilities located world-wide, is poised to play a crucial role in taking the discovery phase of research to bringing drugs to the market.